Comparison 4. IPTi versus placebo or no IPTi (adverse events).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 SP	4		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.1 Stevens‐Johnson syndrome	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.2 Fever	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.3 Loss of appetite	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.4 Weakness	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.5 Skin	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.6 Gastrointestinal	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.7 Respiratory	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.8 Laboratory abnormalities	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.9 Thrombocytopenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.10 Elevated aspartate aminotransferase	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.11 Elevated alanine aminotransferase	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1.12 Neutropenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2 DHAP	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2.1 Fever	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2.2 Thrombocytopenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2.3 Elevated aspartate aminotransferase	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2.4 Elevated alanine aminotransferase	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.2.5 Neutropenia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected